These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30853427)

  • 1. Identifying Factors That Predict the Prescription of Non-vitamin K Antagonist Oral Anticoagulants in Older Individuals With Atrial Fibrillation.
    Shurrab M; Ko DT; McElhaney J; Henderson M; Danon A; Quinn KL; O'Donnell D; Crystal E; Newman D
    J Am Med Dir Assoc; 2019 Aug; 20(8):984-987. PubMed ID: 30853427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.
    Urbaniak AM; Strøm BO; Krontveit R; Svanqvist KH
    Drugs Aging; 2017 Aug; 34(8):635-645. PubMed ID: 28710707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults.
    Fohtung RB; Novak E; Rich MW
    J Am Geriatr Soc; 2017 Nov; 65(11):2405-2412. PubMed ID: 28832920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
    Zhu J; Alexander GC; Nazarian S; Segal JB; Wu AW
    Pharmacotherapy; 2018 Sep; 38(9):907-920. PubMed ID: 29920705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation.
    Moulson N; McIntyre WF; Oqab Z; Yazdan-Ashoori P; Quinn KL; van Oosten E; Hopman WM; Baranchuk A
    Postgrad Med J; 2017 Jun; 93(1100):308-312. PubMed ID: 27307471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.
    Bellinge JW; Paul JJ; Walsh LS; Garg L; Watts GF; Schultz C
    Med J Aust; 2018 Jan; 208(1):18-23. PubMed ID: 29320668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
    Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in oral anticoagulant use - A 10-year retrospective analysis from a general medicine department of a tertiary care hospital in south India.
    Thomas VV; Lenin A; George TK; Thenmozhi M; Iyadurai R; Sudarsanam TD
    J Postgrad Med; 2024 Apr; 70(2):77-83. PubMed ID: 37470633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
    Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
    Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies.
    Zhang C; Gu ZC; Ding Z; Shen L; Pan MM; Zheng YL; Lin HW; Pu J
    Thromb Res; 2019 Feb; 174():16-23. PubMed ID: 30551039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
    Weitz JI; Semchuk W; Turpie AG; Fisher WD; Kong C; Ciaccia A; Cairns JA
    Clin Ther; 2015 Nov; 37(11):2506-2514.e4. PubMed ID: 26481493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients.
    Tedla YG; Schwartz SM; Silberman P; Greenland P; Passman RS
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104718. PubMed ID: 32122777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population.
    Shurrab M; Crystal E; O'Donnell D; Navare H; Neves P; Khatib R; Lashevsky I; Newman D
    J Interv Card Electrophysiol; 2017 Apr; 48(3):261-266. PubMed ID: 28091833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Aug; 72(2):105-112. PubMed ID: 29519547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.